Bristol-Myers Squibb Company

Valuation Analysis

About the Company

Bristol-Myers Squibb Company en bref

Bristol-Myers Squibb Company (BMY) is currently trading at 47,08 € with a market capitalization of 96,1 Md €. The trailing P/E ratio stands at 15.13x, with a forward P/E of 8.76x. The 52-week range spans from 37,07 € to 54,83 €; the current price is 14.1% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 15.01%.

💰 Dividende

Bristol-Myers Squibb Company pays an annual dividend of 2,20 € per share, representing a yield of 4.67%. The payout ratio stands at 70.03%.

📊 Avis des analystes

25 analystes évaluent Bristol-Myers Squibb Company (BMY) au consensus : None. L'objectif de cours moyen est de 54,99 €, soit un potentiel de +16.8% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 34,87 € à 65,38 €.

Bristol-Myers Squibb Company : la thèse d'investissement en détail

Bristol-Myers Squibb Company (BMY) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 71.98%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 38.73% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 15.01%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 230.97% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

At a PEG of 177.24, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 7.91x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 8.76x is meaningfully below the trailing 15.13x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Bristol-Myers Squibb Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.